Ahmedabad, India

Rushikesh Udaykumar Roy

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Cadila Healthcare Limited. Active years: 2015.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Rushikesh Udaykumar Roy: Innovator in Pharmaceutical Chemistry

Introduction

Rushikesh Udaykumar Roy is a notable inventor based in Ahmedabad, India. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on polymorphic forms of O-desmethyl-venlafaxine succinate. His research has implications for the development of more effective medications.

Latest Patents

Rushikesh holds a patent for his invention titled "Polymorphic forms of O-desmethyl-venlafaxine succinate." This patent discloses various polymorphic forms of the compound and outlines the processes for their preparation. His work in this area is crucial for enhancing the therapeutic efficacy of medications derived from this compound.

Career Highlights

Rushikesh is currently employed at Cadila Healthcare Limited, a prominent player in the pharmaceutical industry. His role at the company allows him to apply his expertise in drug formulation and development, contributing to the advancement of healthcare solutions.

Collaborations

Throughout his career, Rushikesh has collaborated with esteemed colleagues, including Shriprakash Dhar Dwivedi and Ashok Prasad. These collaborations have fostered a productive environment for innovation and research within the pharmaceutical sector.

Conclusion

Rushikesh Udaykumar Roy exemplifies the spirit of innovation in pharmaceutical chemistry. His contributions, particularly in the area of polymorphic forms of O-desmethyl-venlafaxine succinate, highlight the importance of research and development in improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…